Chronic kidney disease has a structural problem that most serious conditions do not. It is silent through its early stages, the two tests that detect it are cheap and widely available, and for most of the past three decades there was little to offer anyone diagnosed early beyond blood pressure control. That combination produced a rational enough reason not to look very hard.

That reason has expired. There are now three drug classes with randomized evidence that they slow kidney function decline, and in October the kidney guideline body KDIGO released a draft focused update for public review that extends the strongest of them to a considerably wider group of patients. The screening question and the treatment question have become the same question.

From the Lab to the Ledger

Kidney function is assessed on two axes, and using only one is the most common mistake. Estimated glomerular filtration rate, calculated from a blood creatinine measurement, describes how much filtering capacity remains. Urine albumin-to-creatinine ratio describes how much protein is leaking through the filter. The second often goes abnormal first, which means a normal eGFR on its own does not rule out early kidney disease.

Both are ordinary tests. A urine albumin ratio needs a single urine sample. The reason it is frequently not ordered is habit rather than cost or difficulty.

What changed on the treatment side began with the SGLT2 inhibitors, drugs originally developed to lower blood sugar by making the kidney excrete glucose. Across thirteen randomized trials in more than ninety thousand participants, they reduced kidney disease progression by around 37 percent, and the benefit held in people without diabetes. The draft KDIGO update now recommends them for adults with kidney disease and type 2 diabetes or heart failure regardless of albumin leakage, and across a range of albuminuria and filtration thresholds beyond that.

Two further classes sit alongside them. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, is recommended on top of maximum tolerated blood pressure therapy for people with diabetes, albuminuria and reasonable kidney function, and is suggested for selected people without diabetes. GLP-1 based therapies carry a strong recommendation for people with type 2 diabetes and kidney disease at high cardiovascular risk.

Bio-Pipeline Ledger

eGFR from serum creatinine: universally available, validated, and insufficient alone, since early disease often shows up first as protein in the urine.

Urine albumin-to-creatinine ratio: cheap, validated, and underused. The draft guideline leans on it heavily for both diagnosis and risk stratification.

Cystatin C as a confirmatory GFR marker: increasingly preferred where creatinine may mislead, including during GLP-1 based treatment where body composition shifts. Available, with access uneven.

SGLT2 inhibitors: approved and the foundation of modern treatment, with roughly a 37 percent reduction in progression across pooled trials and benefit in people with and without diabetes.

Finerenone and other non-steroidal MRAs: approved, with randomized evidence in diabetic kidney disease and a weaker suggestion in non-diabetic disease. Requires potassium monitoring two to four weeks after starting.

The Clinical Reality Check

The practical takeaway is narrow and concrete. If you have type 2 diabetes, high blood pressure, heart failure, obesity, or a family history of kidney disease, the two tests that matter are an eGFR and a urine albumin ratio, and it is worth asking specifically whether the second was done. A great many people have had the blood test and not the urine test, which is the most common way early kidney disease goes unrecorded.

What deserves honest qualification is the strength of the newer recommendations. The SGLT2 inhibitor evidence is strong and broad. The finerenone recommendation outside diabetes is weaker, graded as a suggestion rather than a recommendation, and the draft explicitly says it is not a foundational therapy for most people without diabetes. It also does not apply to polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis, which are managed differently. These distinctions matter because the headline version of this story tends to flatten them.

The document itself is a public review draft, not final guidance. It reflects where the evidence has landed and the direction of travel, and it may change before publication. Treating it as settled is premature.

None of these drugs is free of consequence. SGLT2 inhibitors cause a small early drop in eGFR that is expected and not a reason to stop, carry a risk of genital infections, and should be paused around major surgery or prolonged fasting. Finerenone raises potassium. Both require a prescriber who knows the patient's full picture, and the draft itself flags cost and access as real barriers.

What has genuinely changed is the answer to the old question of why bother finding it early. There is now something to do about it, which makes the two cheap tests worth asking for by name.